Karyopharm Therapeutics I... (KPTI)
NASDAQ: KPTI
· Real-Time Price · USD
4.40
0.04 (0.92%)
At close: Jun 13, 2025, 3:59 PM
4.50
2.27%
After-hours: Jun 13, 2025, 05:56 PM EDT
0.92% (1D)
| Bid | 4.18 |
| Market Cap | 38.02M |
| Revenue (ttm) | 142.13M |
| Net Income (ttm) | -62.52M |
| EPS (ttm) | -11.87 |
| PE Ratio (ttm) | -0.37 |
| Forward PE | -0.65 |
| Analyst | Buy |
| Ask | 4.62 |
| Volume | 28,770 |
| Avg. Volume (20D) | 113,447 |
| Open | 4.22 |
| Previous Close | 4.36 |
| Day's Range | 4.22 - 4.49 |
| 52-Week Range | 3.51 - 17.40 |
| Beta | 0.23 |
About KPTI
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol KPTI
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for KPTI stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
-20%
Karyopharm Therapeutics shares are trading lower a...
Unlock content with
Pro Subscription
7 months ago
+17.86%
Karyopharm Therapeutics shares are trading higher after the company announced that, following the FDA feedback, it will be replacing TSS50, one of the co-primary endpoints in the Phase 3 SENTRY Trial with Abs-TSS.
1 month ago · seekingalpha.com
Karyopharm Therapeutics Inc. (KPTI) Q1 2025 Earnings Call TranscriptKaryopharm Therapeutics Inc. (NASDAQ:KPTI ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Brendan Strong - Senior Vice President, Investor Relations & Corporate Communi...
